Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction of Clinical Response and Remission by Vedolizumab in Moderate to Severe Crohn's Disease
2009-016488-12Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Vedolizumab with Placebo (2 arms). Primary endpoints: Clinical remission at Week 6 in TNF-alpha failure subpopulation and Clinical remission at Week 6 (overall population). Started Oct 2010; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2009-016488-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016488-12.